



Universiteit
Leiden
The Netherlands

Thyroid axis challenges in Leiden Longevity Study

Zutinic, A.

Citation

Zutinic, A. (2022, May 25). *Thyroid axis challenges in Leiden Longevity Study*. Retrieved from <https://hdl.handle.net/1887/3304360>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3304360>

Note: To cite this publication please use the final published version (if applicable).

Curriculum Vitae

Ana Žutinić was born on the 10th of June 1988 in Zagreb, Croatia. She attended primary education in Croatia and obtained the International General Certificate of Secondary Education and International Baccalaureate at the International School of The Hague in The Netherlands in 2006.

She commenced studies at Leiden University the following year, where she earned both Bachelor and Master degrees in Biomedical Sciences and Medicine, with an exchange to Heidelberg University and extracurricular laboratory work on diabetic nephropathy with the group of prof. dr. J.A. Bruijn. During this time she was active as a teaching assistant, Board member of Leiden Model United Nations Foundation (winning the Harvard World MUN Award), member of the Leiden Student Council, President of International Student Network, President of International Student Representation and member of the Van Bergen Fund Advisory Board. She is an alumna of the Leiden Leadership Program of Leiden University Honors Academy.

In 2016, she started a PhD project as co-principal investigator and lead trial physician where she set up and managed two EU Horizon 2020 studies with drugs investigating healthy aging in participants from Leiden Longevity Study, which she completed in two years. These studies were part of an EU Horizon 2020 consortium THYRAGE (2016-2021) investigating the role of the thyroid axis in healthy aging and age related diseases. She defended her thesis in Leiden following the COVID-19 lockdown.